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Predicting natural product value, an exploration of 
anti-TB drug space  
Yousef Dashti,a Tanja Grkovica and Ronald J Quinna*  
Mycobacterium tuberculosis (Mtb) still remains a deadly pathogen two decades after the 
announcement of tuberculosis (TB) as a global health emergency by the World Health 
Organization. In last few years new drug combinations are showing promising potential to 
significantly shorten TB treatment times. However there are very few new chemical entities 
being developed to treat this global threat. From January 1990 to December 2012, 949 anti-
mycobacterium natural products were reported in the literature. Here we present a 
perspective based on an analysis of the drug-like properties of the reported anti-
mycobacterium natural products in order to assess drug potential.  
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1 Introduction 
Tuberculosis (TB), an illness that most commonly results from 
infection by Mycobacterium tuberculosis (Mtb), has been 
responsible for the death of almost 30 million people around the 
world in the last decade.1 Currently Mtb is the second most 
deadly pathogen after human immunodeficiency virus (HIV). 
One third of the world’s population is thought to be infected 
with Mtb and 10% of those carry a lifetime risk of developing 
the disease.1 
TB can be cured by long multidrug regimes (6-12 months) but, 
due to a number of factors including limited access to diagnosis 
and treatment in developing countries, the spread of HIV, and 
the emergence of multi- and extensively drug-resistant Mtb 
strains, tuberculosis still remains a leading cause of death in the 
world.2, 3 In addition to the resistance-mediated decline in 
efficacy, current anti-TB drugs have side effects, difficulties 
with dosing regimens and they are unable to combat latent TB. 
New efficacious and affordable chemotherapeutics are needed 
in order to improve patient outcomes, reduce side effects, 
shorten treatment regiment, reduce the emergence of resistance 
strains as well as complications associated with HIV co-
infections. 
Nature is a generous source of active compounds. Investigation 
of the correlation between biosynthetic enzymes and 
therapeutic targets identified that an imprint of the recognition 
of biosynthetic protein surfaces is transferred to recognition of 
therapeutic protein target surfaces. A similar protein fold 
topology has been demonstrated in a study of different targets 
of the same natural product.4-6 This correlation of biosynthetic 
and target proteins explains both the success of compound 
libraries based on natural product starting points and why 
natural products are validated starting points for drug design.7-9 
Compared to synthetic compounds, nature-derived molecules 
have a higher degree of diversity, and an average increase of 
heteroatoms. A study by Feher and Schmidt revealed that 
natural products are more similar to drugs then molecules 
obtained from combinatorial synthesis.10 The majority of 
natural products are biologically active and have better ADME 
properties (adsorption, distribution, metabolism, and excretion) 
compared to combinatorial synthetic compounds.10 However, as 
concluded in an investigation by Shoichet et al., 83% of core 
ring scaffolds present in natural products (NPs) are absent from 
the majority of screening libraries and consequently the large 
compound libraries used in high throughput screening (HTS) 
may not reflect the rich diversity of smaller natural product-
based libraries.11 It has been suggested that inclusion of 
molecules containing scaffolds present in NPs in these 
compound libraries would improve hit rates.11 
The importance of natural products in antibacterial drug 
discovery is undeniable. As documented by Newman and 
Cragg,12 just 3 of the 20 antibacterial classes used in the clinic 
are from synthetic sources and about 70% of antibiotics are 
either natural products or semi-synthetic natural product 
derivatives. The peptide actinomycin, a streptomycete-derived 
compound, was the first reported natural product that inhibited 
in vitro growth of Mtb.13 The aminoglycoside streptomycin 1, 
isolated from Streptomyces griseus, was the first successful 
Page 1 of 9 Natural Product Reports
NPR Highlight 
2 | Nat. Prod. Rep., 2014, 32, xxx-yyy This journal is © The Royal Society of Chemistry 2012 
antibiotic used in chemotherapy of tuberculosis.14 Kanamycin 
(2), a compound related to streptomycin,15 and its semi-
synthetic analogue amikacin (3)16 are part of the second line 
chemotherapy of TB. Rifampicin (4), a semi-synthetic analogue 
 
 
of rifamycin,17 cycloserine (5),18 p-aminosalisylic acid (6),19 
and cyclic peptides capreomycin 1A (7)20, 21 and viomycin 
(8),22, 23 are other examples of nature-derived anti-tuberculosis 
drugs. Reports of anti-TB activity of the natural product 
nicotinamide led to a reinvestigation of the related synthetic 
compound isoniazid (9) which is now one of the most important 
first line drugs used in tuberculosis chemotherapy. 
Subsequently an isostere of isoniazid, pyrazinamide (10), was 
synthesized as a potent anti-TB drug.24 
Pyrazinamide, rifampicin and isoniazid are three out of the four 
components of first line TB treatment. The aminoglycosides 
streptomycin, kanamycin and amikacin as well as cyclic 
peptides, capreomycin and viomycin, are among the second line 
drugs. These molecules also play an important role in new 
treatment regimens for improving efficacy and shortening TB 
chemotherapy.25 Since these nature-derived compounds in 
combination with synthetic TB drugs were successful in 
treatment of TB and have led to an initial decline of TB, 
investigations for new structural class of antibiotics as anti-
tuberculosis agents almost halted in the 1960s after the 
discovery of rifampicin.26 
Following the emergence of multi- and extensively-drug 
resistant Mtb strains in addition to comorbidity with HIV, the 
number of TB-related deaths has significantly increased. In 
1993 the World Health Organization (WHO) declared TB a 
global health emergency and after two decades the report of 
WHO in 2012 indicates that TB still remains a global threat.27, 
28  
During the last five years some promising compound 
candidates entered the TB drug pipeline.25 Except for a few 
compounds that were first discovered as anti-mycobacterial 
molecules and consequently developed as TB drug candidates, 
many of these are repurposed compounds that were already 
used for treatment of other diseases. While the majority of 
approved drugs currently used in TB treatment are nature-
derived molecules, all of the TB drug candidates in clinical 
trials, with the exception of rifapentine (11), are from synthetic 
sources. Many natural products have been reported to have 
activity against mycobacteria during the last two decades and 
are covered by a number of recent comprehensive reviews of 
anti-mycobacterium natural products.29-34 However, none of 
these compounds had been developed for treatment of TB. 
Here, we review the literature and present a perspective based 
on an analysis of the drug-like properties of the anti-
mycobacterium natural products. 
 
2 Physicochemical properties of TB drugs and anti-
mycobacterium natural products 
The activity of any molecule is generally dependent upon the 
compound being able to permeate the cell membrane in order to 
reach and modify the target. It is possible to predict the cell 
permeability and bioavailability of each molecule by examining 
the physicochemical properties of the compound. Lipinski and 
coworkers analyzed around 90% of orally active drug 
candidates that reached phase II clinical trials in order to 
understand which factors are responsible for compound attrition 
in clinical development. Their investigation resulted in the “rule 
of five” (Ro5), based on a simple set of easily calculated 
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physicochemical properties. By comparison of drug-like and 
non-drug-like compounds, they concluded that for a compound 
to be drug-like it should have the cut-off numbers of five or 
multiples of five in four important physicochemical properties. 
These properties are hydrogen bond donor (HBD), hydrogen 
bond acceptor (HBA), molecular weight (MW), and the 
logarithm of the partition coefficient between water and 1-
octanol (log P). According to Lipinski’s rule of five, a drug like 
molecule should have a molecular weight of 500 Da or less, 
equal or less than 5 HBDs, equal or less than 10 HBAs, and a 
partition coefficient, log P, of 5 or less. If two or more 
properties are violated for a compound, there is a high 
probability of lack of oral activity and bioavailability.35 
However, it is important to note that if a compound passes the 
Ro5, there is no guarantee that the molecule is drugable. The 
aim of this rule was to provide a guide for medicinal chemists 
for better selection and design of compounds, in order to reduce 
the attrition during clinical development due to unsatisfactory 
pharmacokinetics.36 Subsequently, some extensions including 
rotatable bond count (ROTB) and polar surface area (PSA) or 
total hydrogen bond count were introduced to complement the 
Ro5. Rotatable bond count is now one of the widely used 
properties to predict oral bioavailability and activity. Generally, 
ligand affinity decreases 0.5 kcal on average for each two 
rotatable bonds.37 If a rigid and a flexible ligand can form the 
same pattern of interaction with a protein (based on hydrogen 
and hydrophobic interaction), the rigid ligand will show much 
stronger binding due to lower entropic losses.38 A molecule 
with 10 or fewer rotatable bonds, polar surface area equal to or 
less than 140 Å (hydrogen bond donors and acceptors equal or 
fewer than 12), will have a high possibility of being a good 
orally bioavailable drug.39   
Herein, the four individual Lipinski properties HBD, HBA, 
MW, and log P along with ROTB and PSA were analyzed for 
39 TB drugs (approved and candidates in clinical trials) as well 
as 949 anti-tuberculosis NPs reported between January 1990 to 
December 2012. InstantJChem 3.0.4. [Instant JChem 3.0.4, 
2009 ChemAxon Ltd. (http://www.chemaxon.com)] was used 
to calculate the physicochemical parameters of each molecule. 
The following paragraphs are devoted to discussion of the 
physicochemical properties of TB drugs, followed by the 
physicochemical properties of anti-mycobacterial NPs and 
comparison between these two sets.  
2.1 Physicochemical properties of TB drugs  
The calculated data for physicochemical properties of approved 
TB drugs and candidates in clinical trials are shown in Table 1. 
The percentage of TB drugs compliant with Lipinski’s rule of 
five is depicted in Figure 1. Almost 77% of TB drugs comply 
with all of the Lipinski’s parameters or have just one violation 
while 23 % (nine drugs) have two or more violations. Five of 
the nine TB drugs that violate the Ro5 are 
intravenous/injectable drugs (streptomycin, kanamycin, 
amikacin, capreomycin, and viomycin). The remaining four are 
orally bioavailable drugs (rifampicin and its analogue 
refapentine, the synthetic drugs bedaquiline (TMC207) (12) and 
the nitroimidazole delamanid (OPC67683) (13). With the 
exception of the approved drug rifampicin, the other three 
compounds are drug candidates in clinical trials. Refapentine is 
a repurposed compound, which is currently in the phase II 
clinical trials, while bedaquiline and delamanid are new 
chemical entities in phase II and phase III respectively.25 
 
The histograms for molecular weight (MW), calculated log P, 
hydrogen bond donors (HBD) and acceptors (HBA) are 
depicted in Figure 2 (purple bars). About 51% of TB drugs are 
distributed between molecular weights of 300-500 Da and are 
all synthetic molecules. Nature-derived TB drugs either possess 
the lowest (cycloserine, pyrazinamide, isoniazid, and p-
aminosalicylic acid) or the highest molecular weight 
(rifampicin, rifapentine, capreomycin, and viomycin).  
The distribution of the calculated log P (Figures. 2b and S1) 
showed a wide range of variability. The majority of compounds 
are distributed between log P of -3 to 5 and showed a bimodal 
distribution with peaks in the range of -1 to 1 and 3 to 5. Cyclic 
peptides, capreomycin and viomycin are the most polar TB 
drugs with log P of around -11. On the other hand, 10% of the 
TB drugs which all are synthetic compounds have calculated 
log P of more than 5. These include clofazimine (14) and the 
drug candidates TMC207, OPC-67683, C215 (15). Overall 
synthetically-derived TB drugs possess higher Log P values 
compared to the nature-derived TB drugs (Figure S1).  
The distribution of hydrogen bond donors (HBD) revealed a 
maximum at 1 and then steadily decreased, while a wide range 
of variability was observed in the distribution histogram of 
hydrogen bond acceptors (HBA) of the TB drugs. Almost 18% 
percent of the compounds had violations from the HBD and 
HBA cutoff numbers 5 and 10, respectively. All of these are 
nature-derived drugs including streptomycin, kanamycin, 
amikacin, capreomycin and viomycin as well as the rifamycins 
analogues, rifampicin and rifapentine.  
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Table 1 Physicochemical properties of 39 approved TB drugs and candidates in clinical trials.  
 Nature-derived TB drugs   First line drugs  Third line drugs 
       Synthetic TB drugs  Second line drugs  Candidates in clinical trials 
 
 
 
 
     
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Pie chart presentation of the percentage of TB drugs (left) and anti-mycobacterium natural 
products (right) compliant with Lipinski’s rule of five.  
 
 Name MW Log P HBD HBA PSA ROTB Ro5 No. Violations 
 Rifampicin 822.94 2.77 6 14 220.15 5 Fail 3 
Isoniazid 137.14 -0.69 2 3 68.01 1 Pass 0 
Pyrazinamide 123.11 -1.23 1 3 68.87 1 Pass 0 
 Ethambutol 204.31 -0.06 4 4 64.52 9 Pass 0 
 Streptomycin 581.57 -7.65 14 19 331.43 9 Fail 3 
Kanamycin 484.50 -7.06 11 15 282.61 6 Fail 2 
Amikacin 585.60 -8.58 13 17 331.94 10 Fail 3 
Cycloserine 102.09 -2.42 2 3 64.35 0 Pass 0 
p-aminosalicylic acid 153.14 0.83 3 4 83.55 1 Pass 0 
Capreomycin 668.71 -11.00 15 14 375.92 10 Fail 3 
Viomycin 685.69 -11.05 16 15 390.36 10 Fail 3 
 Ethionamide 166.24 1.33 1 1 38.91 2 Pass 0 
Terizidone 302.29 -0.38 2 6 101.38 4 Pass 0 
Prothionamide 180.27 1.77 1 1 38.91 3 Pass 0 
Thioacetazone 236.29 0.90 3 2 79.51 3 Pass 0 
Ciprofloxacin 331.34 -0.81 2 6 72.88 3 Pass 0 
Ofloxacin 361.37 0.65 1 7 73.32 2 Pass 0 
Levofloxacin 361.37 0.65 1 7 73.32 2 Pass 0 
Clavulanate 199.16 -1.52 2 5 87.07 2 Pass 0 
Meropenem 383.46 -4.35 3 6 110.18 5 Pass 0 
Clofazimine 472.41 7.81 1 3 27.63 4 Pass 1 
Moxifloxacin 401.43 -0.50 2 7 82.11 4 Pass 0 
Gatifloxacin 375.39 -0.58 2 7 82.11 4 Pass 0 
Linezolid 337.35 0.64 1 5 71.11 4 Pass 0 
Sutezolid 353.41 1.22 1 4 61.88 4 Pass 0 
AZD5847 465.40 0.78 2 7 125.57 7 Pass 0 
SQ109 330.55 4.64 2 2 24.06 9 Pass 0 
AU1235 324.34 3.70 2 1 41.13 2 Pass 0 
TMC207 555.51 7.13 1 4 45.59 8 Fail 2 
DNB1 361.31 2.41 1 7 139.20 8 Pass 0 
BTZ043 431.39 3.65 0 7 96.95 3 Pass 0 
PA-824 359.26 4.14 0 6 91.33 6 Pass 0 
BM212 414.37 4.75 0 2 11.41 4 Pass 0 
OPC-67683 534.48 6.14 0 8 103.80 9 Fail 2 
Metronidazole 171.15 -0.46 1 4 83.87 3 Pass 0 
C215 333.26 6.11 0 1 17.82 5 Pass 1 
VI-9376 344.16 4.17 0 4 71.60 2 Pass 0 
 Rifapentine 877.03 3.56 6 14 220.15 6 Fail 3 
 377790 260.29 3.60 0 4 76.53 4 Pass 0 
Tuberculosis drugs Anti-mycobacterium natural products
77% compliant 
with Ro5
85% compliant 
with Ro5
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Figure 2 Physicochemical property histograms of TB drugs (purple) and anti-mycobacterial natural products (red): a) molecular  
weight (MW), b) calculated log P, c) hydrogen bond donors (HBD), d) hydrogen bond acceptors (HBA). 
 
It is a common practice to analyze physicochemical properties 
prior to making chemical libraries. Antibacterial drugs 
however, due to their higher molecular weight and polarity, 
have always been considered as an exception to the rule of 
five.35, 40 The different components of the human cell wall and 
the bacteria suggests a requirement for different 
physicochemical properties of drug compounds for penetration. 
In a study by O’Shea and Moser the authors concluded that 
antibacterial compounds, especially for those active against 
Gram-negative bacteria, have average molecular weights and 
polarity higher than non-antibacterial compounds.40 Gram-
positive and -negative bacteria have different cell wall 
architecture and consequently molecules with ability to 
penetrate these two types of bacteria have different properties 
and occupy different physicochemical space.40 On the other 
hand, although Mycobacterium tuberculosis, based on its 
conserved gene content, is more related to Gram-negative 
bacteria its unique membrane architecture has characteristics of 
both Gram-positive and -negative bacteria.41 This may be the 
reason that marketed anti-TB drugs are widely distributed 
within physicochemical space and do not fall into any defined 
physicochemical area. It has been proposed that screening 
libraries for anti-TB targets should be less restricted and more 
diverse.42  
2.2 Physicochemical properties of anti-mycobacterium natural 
products (949) reported in 1990-2012 timeframe  
A dataset representing 814 compounds reported in the literature 
during the period from January 1990 to December 2011 as well 
as 135 compounds reported from January to December 2012 
was compiled. Only compounds that exhibited MIC ≤ 64 µg ml-
1 or ≥ 75% growth inhibition at 12.5 µg ml-1 or less43 were 
chosen for physicochemical calculations. Histograms of the 
calculated physicochemical properties are depicted in Figure 2 
(red bars). Out of 949 anti-mycobacterium natural products, 
513 compounds showed no violation of Lipinski’s parameters 
and the majority of the rest had violation in either log P, 
molecular weight, or both of those (Figure S2). The histogram 
of molecular weight (Figure 2a) followed a Gaussian 
distribution and showed a peak at 350-400 Da. About 30% of 
the analyzed compounds had molecular weights more than 500 
Da. The molecular weight distribution was similar to that 
reported by Feher and Schmidt,10 as well as to the molecular 
weight distribution of 126,140 natural products from Dictionary 
of Natural Products which was previously examined for 
Lipinski properties.44 
Similar to the previous analysis of natural products,10, 44 the 
calculated log P histogram of anti-mycobacterium natural 
products (Figure 2b) showed a normal distribution, however, a 
shift to a higher log P values was noticed for anti-
mycobacterium natural products compared to all natural 
products. In contrast to TB drugs where 41% had negative 
calculated log P, a very small percentage (3%) of the active 
natural products showed a negative log P value. Another 
difference between these two sets was observed in the range of 
the log P -1 and 1. While about 33% of TB drugs have log P 
value between -1 and 1, only a small percentage (3.5%) of the 
anti-mycobacterium natural products possess these log P 
values. In the range of 0 to 3 the anti-mycobacterium natural 
products percentage increased gradually and reached a 
maximum 18% at log P 3 with the same percentage at log P 4 
and 5 after which the distribution fell off. The histogram 
showed that around 34% of the compounds violated the 
Lipinski cutoff with a log P of over 5.  
The distribution of hydrogen bond donors (HBD) is depicted in 
Figure 2c. Similar to TB drugs the distribution showed a peak 
at 1 followed by a steady decrease. About 6% of these anti-
mycobacterium NPs had hydrogen bond donors over than 5. In 
contrast to TB drugs, the histogram of hydrogen bond acceptors 
(HBA) (Figure 2d) was Gaussian. It showed a peak at 3 that 
included 20% of the compounds. Only a small percentage of 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
0 50
 
10
0 
15
0 
20
0 
25
0 
30
0 
35
0 
40
0 
45
0 
50
0 
55
0 
60
0 
65
0 
70
0 
75
0 
80
0 
85
0 
90
0 
95
0 
10
00
 
M
or
e 
MW 
P
er
ce
nt
ag
e 
P
er
ce
nt
ag
e 
0"
2"
4"
6"
8"
10"
12"
14"
16"
18"
20"
(1
1
"
(1
0
"
(9
"
(8
"
(7
"
(6
"
(5
"
(4
"
(3
"
(2
"
(1
"
0
"
1
"
2
"
3
"
4
"
5
"
6
"
7
"
8
"
9
"
1
0
"
M
o
re
"
Log P 
P
er
ce
nt
ag
e 
0"
5"
10"
15"
20"
25"
30"
35"
0" 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" More"
HBD 
P
er
ce
nt
ag
e 
0"
5"
10"
15"
20"
25"
0" 1" 2" 3" 4" 5" 6" 7" 8" 9" 10" More"
HBA 
a b 
c d 
Page 5 of 9 Natural Product Reports
NPR Highlight 
6 | Nat. Prod. Rep., 2014, 32, xxx-yyy This journal is © The Royal Society of Chemistry 2012 
anti-mycobacterium natural products (around 5%) had 
hydrogen bond donors higher than 5 and hydrogen bond 
acceptors greater than 10, while 18% of TB drugs were found 
to violate these cutoff numbers.    
Polar surface area distribution (Fig. S3a) demonstrated a peak 
of distribution at 50-60 and about 12% of the analyzed 
compounds had a polar surface area of over 140. The 
distribution of the number of rotatable bonds (Fig. S3b) showed 
a wide range of flexibility. The maximum of distribution was in 
the range of 0 to 2 rotatable bonds with each possessing around 
12-14% of the molecules. About 18% of the analyzed 
compounds exceed the number of rotatable bond cutoff of 10. 
The majority of those were molecules that possess aliphatic 
chains in their structure that makes the compounds more 
lipophilic. 
While 77% of TB drugs obeyed Lipinski’s Ro5, the proportion 
of anti-mycobacterium natural products was higher and about 
85% of the compounds had no violation or just one violation of 
Lipinski’s role of five (Figure 1). The result for anti-
mycobacterium natural products is almost similar to the two 
previous analyses of natural products.10, 44 In both 
investigations about 80% of analyzed compounds had less than 
two violations of Ro5. 
 
3 Comparison of anti-mycobacterial natural product 
physicochemical space vs current anti-TB drugs – 
what does it tell us? 
In order to compare the distribution of TB drugs and anti-
mycobacterium natural products in physicochemical space, 
ChemGPS-NP45 was used for principle component  analysis 
(PCA) of the 949 anti-mycobacterium natural products and the 
39 TB drugs (which included both the marketed and promising 
compounds in clinical trials). The first three principle 
components that explained 71% of the variance are plotted in 
Figures 3a and 3b. PC1 describes size, shape, and 
polarizability, PC2 represents aromatic and conjugation related 
properties and PC3 expresses lipophilicity, polarity and H-bond 
capacity.45  
Figure 3a demonstrates the score plot of all TB drugs and 
shows that TB drugs occupy a very broad range of 
physicochemical space. The nature derived TB drugs however, 
can be divided into three clusters shown in cyan ovals. The first 
cluster is representative of polar and high molecular weight 
compounds comprised of aminoglycosides streptomycin, 
kanamycin, and amikacin and the cyclicpeptides capreomycin 
and viomycin. It is important to note that all of these 
compounds are injectable/intravenous drugs. Another cluster 
belongs to the low molecular weight compounds including 
cycloserine, pyrazinamide, isoniazide, and p-aminosalicylic 
acid. The molecular weight of these compounds does not 
exceed 200 Da. The last cluster of nature-based drugs contains 
rifamycines analogues, rifampicin and rifapentine. These orally 
bioavailable drugs possesses the highest molecular weight of 
TB drugs (MW of 822 and 877 Da respectively) with HBDs 
and HBAs exceeding the Lipinski’s rule of five while having a 
log P value within the range. 
The majority of TB drugs from synthetic sources fall into drug-
like physicochemical space. Outliers of synthetic compounds 
are newly introduced compounds in which most of them have 
log P greater than 5 (TMC207, OPC-67683, clofazimine, and 
C215).  
In order to evaluate the 949 anti-mycobacterium natural 
products reported in the 1990-2012 timeframe against TB drug 
physicochemical space, their first three PCs are plotted and 
compared to TB drugs in Figure 3b. Red dots show TB drugs 
and blue dots illustrate anti-mycobacterium natural products. 
Similar to the distribution of synthetic TB drugs, the majority 
of anti-mycobacterium NPs fall into drug-like space. Not many 
are toward the two major categories of nature-based TB drugs. 
 
Figure 3 Score plot of TB drugs and anti-mycobacterium natural products. a) Physicochemical space of 39 approved TB drugs and candidates in 
clinical trials. Cyan ovals are showing the three clusters of natural product-based drugs while the rest of the compounds are synthetic TB drugs. b) 
Comparison of the physicochemical space of 949 anti-mycobacterium natural products (blue dots) with physicochemical space of 39 TB drugs (red 
dots).  
 
Anti-mycobacterium natural products that occur close to the 
cluster of low molecular weight TB drugs are shown in Figure 
S4. The set comprises 23 compounds and the majority are 
phenolics. In addition there are five small molecular weight 
alkaloids containing a similar core ring of imidazolidine or 
pyrrolidine in their structures. 
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Log P plays an important role in drugability of anti-
mycobacterium natural products. The mycobacterial cell wall 
contains a large amount of lipids mainly in form of mycolic 
acids that make a strong hydrophobic layer, which is believed 
to be responsible for the permeability barrier towards 
hydrophilic compounds.46, 47. The high percentage of anti-
mycobacterium natural products (34%) with log P value more 
than 5, demonstrates the ability of lipophilic compounds to pass 
through the waxy cell wall of the mycobacteria in order to 
reach the target enzyme. We have shown that, in contrast to the 
TB drugs which display 33% of log P values between -1 and 1, 
only 3.5% of anti-mycobacterium natural products fall in this 
range. The set consists of 34 molecules that belong to different 
classes of compounds including phenolics and quinones, 
alkaloids, peptides and terpenes. The potent antibacterial 
thiazole peptides nocathiacins I-III (molecules 47-49 in 
supporting information) are among this set. Nocathiacins 
antibiotics are isolated from the fermentation broth of Nocardia 
sp. (ATCC202099)48, 49 and a fungus Amicolaptosis sp. 
(MJ347-81F4).50 These molecules exhibit strong activity 
towards a range of bacteria including M. tuberculosis 
(ATCC35828) with MIC value of ≤ 0.008 µg/ml.51 The 
compounds however, have poor aqueous solubility.51 
Nocathiacin I was used as a lead for development of novel 
semi-synthetic water soluble nocathiacin analogs.52-55 
4 Conclusions 
Natural product-based TB drugs are vital components of first 
and second line TB drugs and have significant efficacy in TB 
treatment. However, the current contribution of nature-derived 
molecules in the TB drug pipeline is very small with only the 
repurposed nature-derived anti-TB compound rifapentine in 
clinical trials. Efforts of the past three decades for identification 
of anti-mycobacterium natural products have been very 
productive. About 949 secondary metabolites belonging to 
various chemical classes are reported to inhibit the growth of 
mycobacterium. Analysis of the physicochemical properties of 
these anti-mycobacterium natural products and comparison 
with the physicochemical properties of TB drugs revealed 
major differences between the log P distribution and the 
molecular weight distribution of these two sets. Anti-
mycobacterium natural products showed a shift to higher log P 
values and only a small percentage (3%) had negative 
calculated log P, while a high percentage of TB drugs (41%) 
had negative log P values. TB drugs showed the maximum 
peak of distribution in the range of log P -1 to 1, while there 
were very few active NPs in this region. A small percentage of 
anti-mycobacterium natural products possess molecular weight 
less than 200 Da whereas many TB drugs have a molecular 
weight less than 200 Da. Principle component analysis of the 
949 anti-mycobacterium natural products and the 39 TB drugs 
using ChemGPS-NP also highlighted that not many secondary 
metabolites are toward the cluster of the low molecular weight 
TB drugs. Of the 949 anti-mycobacterium natural products only 
50 compounds cluster within the two clusters occupied by 
many TB drugs. The structures of the natural products in these 
two clusters, 23 and 34 compounds respectively, are given in 
the Supplementary Information. Within this set the most active 
compounds are MIC = 0.4 µg/ml (H37Ra), MIC = 0.5 µg/ml (M. 
smegmatis), MIC = 8 µM (H37Rv), [low MW] and MIC = 0.4 
µg/ml (H37Ra), MIC = 8.9 µM (H37Ra), MIC = 1 µg/ml 
(H37Rv), MIC = 17 µM (H37Rv), MIC = 6.25 µg/ml (M. 
tuberculosis), MIC = 3.12 µg/ml (M. vaccae),), MIC = ≤ 0.008 
µg/ml (M. tuberculosis) [log P between -1 and +1].  The drug 
space of existing TB drugs may help prioritisation of a 
continuing discovery pipeline of anti-mycobacterium natural 
product and hit-to-lead identification of anti-mycobacterium 
natural products reported in the literature. 
 
 
5 Acknowledgements 
The work was supported by Bill & Melinda Gates Foundation 
Grand Challenges Explorations Grants OPP1008376 and 
OPP1035218 and the Australian Research Council (ARC) 
Linkage Project (LP120100485).   
 
6 References 
 
1. S. H. E. Kaufmann and P. van Helden, Handbook of Tuberculosis: 
Clinics, Diagnostics, Therapy and Epidemiology, Wiley, 2008. 
2. W. H. Organization, Treatment of Tuberculosis Guidelines, 2007. 
3. W. H. Organization, The Global Plan to Stop TB, 2006-2015., 2006. 
4. B. M. McArdle, M. R. Campitelli and R. J. Quinn, J. Nat. Prod., 
2006, 69, 14-17. 
5. B. M. McArdle and R. J. Quinn, ChemBioChem, 2007, 8, 788-798. 
6. E. Kellenberger, A. Hofmann and R. J. Quinn, Nat. Prod. Rep., 2011, 
28, 1483-1492. 
7. M. A. Koch and H. Waldmann, Drug Discov. Today, 2005, 10, 471-
483. 
8. M. A. Koch, L. O. Wittenberg, S. Basu, D. A. Jeyaraj, E. 
Gourzoulidou, K. Reinecke, A. Odermatt and H. Waldmann, 
Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 16721-16726. 
9. R. Breinbauer, I. R. Vetter and H. Waldmann, Angew. Chem. Int. Ed., 
2002, 41, 2879-2890. 
10. M. Feher and J. M. Schmidt, J. Chem. Inf. Comput. Sci., 2003, 43, 
218-227. 
11. J. Hert, J. J. Irwin, C. Laggner, M. J. Keiser and B. K. Shoichet, Nat. 
Chem. Biol., 2009, 5, 479-483. 
12. D. J. Newman and G. M. Cragg, J. Nat. Prod., 2007, 70, 461-477. 
13. H. B. Woodruff and S. A. Waksman, Ann. N. Y. Acad. Sci., 1960, 89, 
287-298. 
14. S. A. Waksman, Adv. Appl. Microbiol., 1969, 11, 1-16. 
15. M. J. Cron, O. B. Fardig, D. L. Johnson, H. Schmitz, D. F. 
Whitehead, I. R. Hooper and R. U. Lemieux, J. Am. Chem. 
Soc., 1958, 80, 2342-2342. 
16. H. Kawaguchi, T. Naito, S. Nakagawa and K. I. Fujisawa, J. 
Antibiot., 1972, 25, 695-708. 
17. W. J. Burman, K. Gallicano and C. Peloquin, Clin. Pharmacokinet., 
2001, 40, 327-341. 
18. F. A. Kuehl, F. J. Wolf, N. R. Trenner, R. L. Peck, R. P. Buhs, E. 
Howe, I. Putter, B. D. Hunnewell, R. Ormond, G. Downing, J. 
E. Lyons, E. Newstead, L. Chaiet and K. Folkers, J. Am. Chem. 
Soc., 1955, 77, 2344-2345. 
19. J. Lehmann, Lancet, 1946, 1, 15-16. 
20. E. B. Herr, Jr. and M. O. Redstone, Ann. N. Y. Acad. Sci., 1966, 135, 
940-946. 
21. S. Nomoto, T. Teshima, T. Wakamiya and T. Shiba, Tetrahedron, 
1978, 34, 921-927. 
22. B. W. Bycroft, Chem. Commun., 1972, 0, 660-661. 
Page 7 of 9 Natural Product Reports
NPR Highlight 
8 | Nat. Prod. Rep., 2014, 32, xxx-yyy This journal is © The Royal Society of Chemistry 2012 
23. T. Kitagawa, T. Miura, K. Fujiwara and H. Taniyama, Chem. Pharm. 
Bull., 1972, 20, 2215-2225. 
24. M. T. Gutierrez-Lugo and C. A. Bewley, J. Med. Chem., 2008, 51, 
2606-2612. 
25. A. Zumla, P. Nahid and S. T. Cole, Nat. Rev. Drug Discov., 2013, 12, 
388-404. 
26. N. Maggi, C. R. Pasqualucci, R. Ballotta and P. Sensi, 
Chemotherapy, 1966, 11, 285-292. 
27. W. H. Organization, World Health Forum, 1993. 
28. W. H. Organization, Global Tuberculosis Report 2012. 
29. B. R. Copp, Nat. Prod. Rep., 2003, 20, 535-557. 
30. G. F. Pauli, R. J. Case, T. Inui, Y. Wang, S. Cho, N. H. Fischer and 
S. G. Franzblau, Life Sci., 2005, 78, 485-494. 
31. A. L. Okunade, M. P. Elvin-Lewis and W. H. Lewis, Phytochemistry, 
2004, 65, 1017-1032. 
32. B. R. Copp and A. N. Pearce, Nat. Prod. Rep., 2007, 24, 278-297. 
33. A. García, V. Bocanegra-García, J. P. Palma-Nicolás and G. Rivera, 
Eur. J. Med. Chem., 2012, 49, 1-23. 
34. C. E. Salomon and L. E. Schmidt, Curr. Top. Med. Chem., 2012, 12, 
735-765. 
35. C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Adv. 
Drug Deliv. Rev., 1997, 23, 3-25. 
36. C. A. Lipinski, Drug Discov. Today Technol., 2004, 1, 337-341. 
37. P. R. Andrews, D. J. Craik and J. L. Martin, J. Med. Chem., 1984, 27, 
1648-1657. 
38. G. Klebe and H. J. Böhm, J. Recept. Sig. Transd., 1997, 17, 459-473. 
39. D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward 
and K. D. Kopple, J. Med. Chem., 2002, 45, 2615-2623. 
40. R. O’Shea and H. E. Moser, J. Med. Chem., 2008, 51, 2871-2878. 
41. L. M. Fu and C. S. Fu-Liu, Tuberculosis, 2002, 82, 85-90. 
42. A. Koul, E. Arnoult, N. Lounis, J. Guillemont and K. Andries, 
Nature, 2011, 469, 483-490. 
43. J. Secrist, S. Anathan, C. Kwong, J. Maddry, R. Reynolds, A. 
Poffenberger, M. Michael, L. Miller, J. Krahenbuh, L. Adams, 
A. Biswas, S. Franzblau, D. Rouse, D. Winfield and J. Brooks, 
Antimicrob. Agents Chemother., 2001, 45, 1943-1946. 
44. R. J. Quinn, A. R. Carroll, N. B. Pham, P. Baron, M. E. Palframan, L. 
Suraweera, G. K. Pierens and S. Muresan, J. Nat. Prod., 2008, 
71, 464-468. 
45. J. Larsson, J. Gottfries, S. Muresan and A. Backlund, J. Nat. Prod., 
2007, 70, 789-794. 
46. D. E. Minnikin, Lipids: complex lipids, their chemistry, biosynthesis 
and roles, Academic Press, London, 1982. 
47. N. Rastogi, K. S. Goh and H. L. David, Antimicrob. Agents 
Chemother., 1990, 34, 759-764. 
48. W. Li, J. E. Leet, A. H. A., D. R. Gustavson, D. M. Brown, L. 
Turner, K. Brown, J. Clark, H. Yang, J. Fung-Tomc and K. S. 
Lam, J. Antibiot., 2003, 56, 226-231. 
49. J. E. Leet, W. Li, A. H. A., J. A. Maston, S. Huang, R. Huang, J. L. 
Cantone, D. Drexler, R. A. Dalterio and K. S. Lam, J. 
Antibiot., 2003, 56, 232-242. 
50. T. Sasaki, T. Otani, H. Matsumoto, N. Unemi, M. Hamada, T. 
Takeuchi and M. Hori, J. Antibiot., 1998, 51, 715-721. 
51. M. J. Pucci, J. J. Bronson, J. F. Barrett, K. L. DenBleyker, L. F. 
Discotto, J. C. Fung-Tomc and Y. Ueda, Antimicrob. Agents 
Chemother., 2004, 48, 3697-3701. 
52. L. Xu, A. K. Farthing, J. F. Dropinski, P. T. Meinke, C. McCallum, 
E. Hickey and K. Liu, Bioorg. Med. Chem. Lett., 2013, 23, 
366-369. 
53. L. B. Xu, A. K. Farthing, J. F. Dropinski, P. T. Meinke, C. 
McCallum, P. S. Leavitt, E. J. Hickey, L. Colwell, J. Barrett 
and K. Liu, Bioorg. Med. Chem. Lett., 2009, 19, 3531-3535. 
54. A. Regueiro-Ren, B. N. Naidu, X. Zheng, T. W. Hudyma, T. P. 
Connolly, J. D. Matiskella, Y. Zhang, O. K. Kim, M. E. 
Sorenson, M. Pucci, J. Clark, J. J. Bronson and Y. Ueda, 
Bioorg. Med. Chem. Lett., 2004, 14, 171-175. 
55. P. Hrnciar, Y. Ueda, S. Huang, J. E. Leet and J. J. Bronson, J. Org. 
Chem., 2002, 67, 8789-8793. 
 
 
 
 
Page 8 of 9Natural Product Reports
  
 
 
 
39x30mm (300 x 300 DPI)  
 
 
Page 9 of 9 Natural Product Reports
